1502 related articles for article (PubMed ID: 14982987)
1. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta.
Jiang Z; Mak TW; Sen G; Li X
Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3533-8. PubMed ID: 14982987
[TBL] [Abstract][Full Text] [Related]
2. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling.
Sato S; Sugiyama M; Yamamoto M; Watanabe Y; Kawai T; Takeda K; Akira S
J Immunol; 2003 Oct; 171(8):4304-10. PubMed ID: 14530355
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Toll-interleukin 1 receptor mediated signaling.
Li X; Qin J
J Mol Med (Berl); 2005 Apr; 83(4):258-66. PubMed ID: 15662540
[TBL] [Abstract][Full Text] [Related]
4. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling.
Yamamoto M; Sato S; Mori K; Hoshino K; Takeuchi O; Takeda K; Akira S
J Immunol; 2002 Dec; 169(12):6668-72. PubMed ID: 12471095
[TBL] [Abstract][Full Text] [Related]
5. Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR .
Jiang Z; Zamanian-Daryoush M; Nie H; Silva AM; Williams BR; Li X
J Biol Chem; 2003 May; 278(19):16713-9. PubMed ID: 12609980
[TBL] [Abstract][Full Text] [Related]
6. Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling.
Gohda J; Matsumura T; Inoue J
J Immunol; 2004 Sep; 173(5):2913-7. PubMed ID: 15322147
[TBL] [Abstract][Full Text] [Related]
7. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway.
Yamamoto M; Sato S; Hemmi H; Hoshino K; Kaisho T; Sanjo H; Takeuchi O; Sugiyama M; Okabe M; Takeda K; Akira S
Science; 2003 Aug; 301(5633):640-3. PubMed ID: 12855817
[TBL] [Abstract][Full Text] [Related]
8. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence.
Stack J; Haga IR; Schröder M; Bartlett NW; Maloney G; Reading PC; Fitzgerald KA; Smith GL; Bowie AG
J Exp Med; 2005 Mar; 201(6):1007-18. PubMed ID: 15767367
[TBL] [Abstract][Full Text] [Related]
9. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction.
Oshiumi H; Matsumoto M; Funami K; Akazawa T; Seya T
Nat Immunol; 2003 Feb; 4(2):161-7. PubMed ID: 12539043
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of phosphoinositide 3-kinase enhances TRIF-dependent NF-kappa B activation and IFN-beta synthesis downstream of Toll-like receptor 3 and 4.
Aksoy E; Vanden Berghe W; Detienne S; Amraoui Z; Fitzgerald KA; Haegeman G; Goldman M; Willems F
Eur J Immunol; 2005 Jul; 35(7):2200-9. PubMed ID: 15940673
[TBL] [Abstract][Full Text] [Related]
11. Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation.
Cusson-Hermance N; Khurana S; Lee TH; Fitzgerald KA; Kelliher MA
J Biol Chem; 2005 Nov; 280(44):36560-6. PubMed ID: 16115877
[TBL] [Abstract][Full Text] [Related]
12. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation.
Meylan E; Burns K; Hofmann K; Blancheteau V; Martinon F; Kelliher M; Tschopp J
Nat Immunol; 2004 May; 5(5):503-7. PubMed ID: 15064760
[TBL] [Abstract][Full Text] [Related]
13. Cutting Edge: NF-kappaB-activating kinase-associated protein 1 participates in TLR3/Toll-IL-1 homology domain-containing adapter molecule-1-mediated IFN regulatory factor 3 activation.
Sasai M; Oshiumi H; Matsumoto M; Inoue N; Fujita F; Nakanishi M; Seya T
J Immunol; 2005 Jan; 174(1):27-30. PubMed ID: 15611223
[TBL] [Abstract][Full Text] [Related]
14. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex.
Youn HS; Lee JY; Fitzgerald KA; Young HA; Akira S; Hwang DH
J Immunol; 2005 Sep; 175(5):3339-46. PubMed ID: 16116226
[TBL] [Abstract][Full Text] [Related]
15. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo.
Shim JH; Xiao C; Paschal AE; Bailey ST; Rao P; Hayden MS; Lee KY; Bussey C; Steckel M; Tanaka N; Yamada G; Akira S; Matsumoto K; Ghosh S
Genes Dev; 2005 Nov; 19(22):2668-81. PubMed ID: 16260493
[TBL] [Abstract][Full Text] [Related]
16. TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferon-beta.
Oshiumi H; Sasai M; Shida K; Fujita T; Matsumoto M; Seya T
J Biol Chem; 2003 Dec; 278(50):49751-62. PubMed ID: 14519765
[TBL] [Abstract][Full Text] [Related]
17. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction.
Fitzgerald KA; Palsson-McDermott EM; Bowie AG; Jefferies CA; Mansell AS; Brady G; Brint E; Dunne A; Gray P; Harte MT; McMurray D; Smith DE; Sims JE; Bird TA; O'Neill LA
Nature; 2001 Sep; 413(6851):78-83. PubMed ID: 11544529
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif.
Kaiser WJ; Offermann MK
J Immunol; 2005 Apr; 174(8):4942-52. PubMed ID: 15814722
[TBL] [Abstract][Full Text] [Related]
19. Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor participates in activation of the Toll-like receptor 3/4 pathway.
Sasai M; Tatematsu M; Oshiumi H; Funami K; Matsumoto M; Hatakeyama S; Seya T
Mol Immunol; 2010 Mar; 47(6):1283-91. PubMed ID: 20047764
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction.
Uematsu S; Sato S; Yamamoto M; Hirotani T; Kato H; Takeshita F; Matsuda M; Coban C; Ishii KJ; Kawai T; Takeuchi O; Akira S
J Exp Med; 2005 Mar; 201(6):915-23. PubMed ID: 15767370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
